# PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

> **NCT03179410** · PHASE2 · COMPLETED · sponsor: **Andrew J. Armstrong, MD** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03179410
- **Lead sponsor:** Andrew J. Armstrong, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2020-01-09
- **Final completion:** 2020-12-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179410, "PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03179410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*